Please assess the completion status of the following clinical trial:

Trial Title: The Hemophilia Inhibitor Eradication Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male adults or children \> 4 months of age.~2. Severe hemophilia A (FVIII \< 0.01 U/ml).~3. Current or past high-responding inhibitor, anti-FVIII \>= 5.0 B.U., ITI-refractory or ITI-naive.~Exclusion Criteria:~1. Acquired hemophilia or any bleeding disorder other than hemophilia A.~2. Current use of Emicizumab, or if used, \> 8 weeks since last treatment.~3. Use of an experimental drug(s).~4. Surgery anticipated in the next 48 weeks.~5. Life expectancy less than 5 years.~6. Patient/parent/caretaker unable or unwilling to keep a personal diary of bleeding frequency and study drug treatment, make monthly visits and blood draws at weeks 4, 8, 12, 24, 36, and 48.~7. Other illness, condition, or reason in the opinion of the investigator that would make the patient unsuitable for the trial.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eloctate ITI plus Emicizumab (Type: EXPERIMENTAL): Arm A: Eloctate 100 IU/kg every other day by intravenous infusion plus Emicizumab 1.5 mg/kg subcutaneously (following 3 mg/kg/wk x 4 induction) in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
- Eloctate ITI (Type: ACTIVE_COMPARATOR): Arm B: Eloctate 100 IU/kg every other day by intravenous infusion in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).